D. Jayne

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

D. Gladman, E. Svenungsson, F. Houssiau, 2023, Annals of the Rheumatic Diseases.

Avacopan for the Treatment of ANCA-Associated Vasculitis.

P. Merkel, T. Schall, P. Bekker, 2021, The New England journal of medicine.

Intravenous immunoglobulin as sole therapy for systemic vasculitis.

D. Jayne, C. Lockwood, D. R. Jayne, 1996, British journal of rheumatology.

Thyroid disease in ANCA-associated vasculitis: a clinical and epidemiological study

A. Mohammad, Rona M. Smith, D. Jayne, 2024, RMD open.

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.

D. Jayne, Arnaud Bourdin, Michael E. Wechsler, 2024, The New England journal of medicine.

What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides.

D. Jayne, K. de Groot, K. D. Groot, 2005, Clinical nephrology.

Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial

A. Dua, D. Geetha, Jason M Springer, 2023, Annals of the Rheumatic Diseases.

The Improved Kidney Risk Score in ANCA-Associated Vasculitis for Clinical Practice and Trials

J. Jennette, Kate I Stevens, J. Augusto, 2023, Journal of the American Society of Nephrology.

Safety and efficacy of TNF a blockade in relapsing vasculitis

M. Pras, A. Ferrante, F. Ciccia, 2002 .

ANCA-associated vasculitis—treatment standard

A. Chalkia, D. Jayne, 2023, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Long-term surveillance study of rituximab originator treated patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)

J. Barrett, R. Luqmani, Rona M. Smith, 2024, Rheumatology advances in practice.